Oncology Times Broadcast News - Aromatase Inhibitor Better Than Tamoxifen For Initial Adjuvant Therapy For Hormone Receptor Positive Breast Cancer, But Compliance An Issue!

Aromatase Inhibitor Better Than Tamoxifen For Initial Adjuvant Therapy For Hormone Receptor Positive Breast Cancer, But Compliance An Issue!

10/06/09 • 6 min

Oncology Times Broadcast News Aromatase Inhibitor Better than Tamoxifen for Initial Adjuvant Therapy for HR- Positive Breast Cancer, But Compliance an Issue! Cornelis van de Velde at ECCO15-ESMO34 on the largest comparison of an aromatase inhibitor with tamoxifen as initial adjuvant therapy for patients with hormone receptor-positive breast cancer–analysis of results from the TEAM (Tamoxifen Exemestane Adjuvant Multinational) study reported at ECCO15-ESMO34.

Previous Episode

Longer Follow-up Reveals: Aspirin Prevents Cancer in Lynch Syndrome

John Burn talking at ECCO15-ESMO34 in Berlin about his international study showing that aspirin prevented the development of Hereditary Non-Polyposis Colon Cancer in people genetically at risk for the disease.

Next Episode

Swedish Registry Study Shows Hormone Therapy for Prostate Cancer Increased All Cardiovascular Mortality

Oncology Times Broadcast News Swedish Registry Study Shows Hormone Therapy for Prostate Cancer Increased All Cardiovascular Mortality Mieke Van Hemelrijck at ECCO15-ESMO34 on findings that cardiovascular mortality from heart failure and arrhythmia in addition to ischemic heart disease and myocardial infarction increased among patients treated with endocrine therapy—of whatever type—for their prostate cancer.